Background Contracting for HIV service provision is now an established part of the National Health Service commissioning process. AIDS is a heterogeneous condition, comprising various opportunistic illnesses which require different services and which have different resource implications. This study describes the use of hospital services and associated costs for the management of different AIDS defining conditions. Method A retrospective case-notes analysis was performed, of 335 Al DS patients treated at St Mary's Hospital, London, between 1 January 1983 and 30 September 1989, as well as a costing exercise of 37 clinical departments to calculate HIV-related costs.
Introduction
Changes in hospital service provision for people at different stages of HIV infection and related costs have recently been described 1 3 within the context of changing morbidity and mortality patterns observed for patients attending St Mary's Hospital. 4 The use of services and associated costs per patient-year were greatest for patients with an AIDS defining diagnosis. However, the AIDS category is a heterogeneous one. The underlying pathophysiological problem of HIV disease is that of progressive immunosuppression, which manifests itself clinically in a number of conditions: a variety of opportunistic infections or tumours can occur sequentially, concurrently, or both. Each of these opportunistic illnesses is likely to require different combinations of services with different resource implications.
The main purpose of this paper is to describe in more detail the use of services and their associated costs for people with specific AIDS defining conditions. Such information is required by providers and purchasers of services for contracting purposes and resource allocation but to date no such detailed analyses have been produced for UK patients with AIDS.
Methods
Data were abstracted -by one of the authors (E.J.B.) -from the in-patient and out-patient case-notes of 335 patients who developed an AIDS defining diagnosis at St Mary's between 1 January 1982 and 30 September 1989. These 335 patients were 82 per cent of known AIDS cases managed at St Mary's during the study period. 1 The data analysed included demographic characteristics of individual patients and the services used by them during successive in-patient episodes and outpatient visits. Cases were assigned retrospectively to a clinical category at each admission or visit, using a classification system based on the 1987 Centres for Disease Control (CDC) 5 and 1989 CDSC 6 notification systems. The data were analysed using SAS® software.
Data on use of services by each patient for each visit or admission were aggregated and mean units of service use per patient-year were calculated. As the data are not independent, confidence intervals were not calculated. A 'patient-year' was a 365-day period of follow-up at St Mary's Hospital after diagnosis of an AIDS defining condition.
The 335 patients generated 605 AIDS defining diagnoses during the study period, which were aggregated into 17 diagnostic categories, including a number of common diagnostic combinations (see Tables 2a and  2b , below). The number of patients that contributed to each diagnostic category is indicated in Tables 2a and  2b .
The numbers of days on which drugs were prescribed in each diagnostic category were determined. A 'drugday' constituted one day on which one drug was prescribed. Prescriptions for multiple drugs for the same patient were summed and the number of drugdays per patient-year may therefore exceed 365. Average costs of each test or procedure and average drug costs for normal daily doses were calculated. For this purpose the average St Mary's pharmacy costs for the period October 1989-September 1990 were used. Normal daily doses were obtained in consultation with the HIV-pharmacist for specialized drugs and from the British National Formulary 7 for routine compounds.
HIV-related workload and associated costs were estimated for each of the 37 departments involved in HIV-related care through a detailed departmental survey. Prices used during the study were for the financial year 1989-1990, but were adjusted to 1993-1994 prices using the Hospital and Community Health Services Revenue (pay and prices) Inflation Index. 8 Detailed methods by which all these cost data were obtained have been described elsewhere. 
Results
Most of the patients who developed an AIDS defining condition during the period were homosexual men with a mean age of 38 when they first developed AIDS. There were very few injecting drug users (Table 1 ). There was no major difference in demographic and transmission characteristics for those diagnosed with an AIDS defining condition before and since 1987.
The average costs for each of the 17 clinical categories are shown in Table 2b . These ranged from £8163 per patient-year for Constitutional Disease (CD) to £42124 per patient-year for patients with Cytomegalovirus (CMV) Disease. Patients with Constitutional Disease or Candidiasis used fewer in-patient and out-patient services and hence the cost per patientyear was less than for patients with Kaposi's sarcoma (KS), Pneumocystis carinii pneumonia (PCP) or other combinations. Similarly, combinations of opportunistic illnesses had greater average costs per patient-year than the single diagnostic categories (Table 2b) . In-patient-related costs comprised between 70 and 90 per cent of total costs per patient-year for most diagnostic categories; patients with cerebral Toxoplasmosis were the only ones for whom in-patient costs were equivalent to out-patient costs (Table 2a) . For most categories, around 80 per cent of in-patient costs were generated by care costs; drug costs accounted for about 10 per cent and the remainder were attributable to tests and procedures. For this reason, cost per in-patient day only varied between £334 [for patients with non-Hodgkin Lymphoma (NHL) and another opportunistic illness (Ol)] and £433 per in-patient day [for patients with CMV Disease] (Table 2a) .
Out-patient costs comprised around 25 per cent of total costs per patient-year. However, average cost per out-patient visit varied from £99 for patients with NHL to £335 for patients with PCP and another Ol (Table  2b ). This variation was mainly due to differing drug costs: out-patient drug costs ranged between 18 per cent for patients with NHL to 71 per cent for patients with PCP and another Ol (Table 2b) .
The above calculations refer to costs per patientyear, but with disease progression, most patients did not remain in the same diagnostic category for 12 months at a time (Table 3) . Thus the median time spent in the PCP category was 9-4 months, but once patients develop additional opportunistic illnesses the median time interval spent in subsequent diagnostic categories n, number of cases contributing to diagnostic categories. Thus 133 patients were seen with an episode of Pneumocystis carinii pneumonia (PCP) and 37 patients were seen with the combination of PCP and an opportunistic tumour (OT); the latter either had had an episode of PCP and subsequently developed an OT or presented with an OT and subsequently developed PCP. Similarly, 18 patients were seen who had a combination of either Non-Hodgkin Lymphoma (NHL) or Primary Lymphoma of the Brain, combined with Kaposi's sarcoma (KS) and another opportunistic illness (Ol). Other Ols include any combination of Constitutional Disease (CD), Neurological Disease (ND), Cryptosporidiosis, Toxoplasmosis, Herpes, Isosporiasis, Cryptococcosis, Histoplasmosis, Atypical Mycobacterial Infection, Chronic Mucocutaneous or Disseminated Herpes Simplex, Progressive Multifocal Leukoencephalopathy or Recurrent Salmonella Septicaemia; any combination of these diagnostic categories by themselves were aggregated within the 'Other Combinations' (OC) category. 'PCP + Ol', patients with PCP and another Ol but excluding OTs;'PCP+ OT+OI', patients with PCP and KS and another Ol; 'KS + OI', patients with KS and another Ol. was on the whole shorter; a similar pattern is observed for patients who first presented with Kaposi's sarcoma.
The use and cost of in-patient and out-patient services for patients who first developed an AIDS defining diagnosis between 1983 and 1986 were compared with those for patients who developed one during 1987-1989. (The data presented here only include those categories with more than ten cases for each time period.) For only one category did the cost per patient-year increase, namely, PCP and an opportunistic tumour (OT ; Table  4b ). This was owing to a marked increase in in-patient expenditure, arising especially from an increase in the mean number of in-patient days. In all other categories costs remained about the same or decreased (Table 4b ). In some categories there were increases in out-patient activity, but costs were offset by reduced use of in-patient services and costs (Tables 4a and 4b ). For PCP alone or in combination with other diagnoses, increased out-patient expenditure was mainly due to an increased expenditure on drugs.
Discussion
Before discussing the salient findings of this study, some of its limitations need to be discussed. A minority of the case-notes were incomplete; some drug charts were missing, tests or procedures may not have been recorded in the case-notes and were therefore inadvertently omitted. When treated within St Mary's, most consultations, investigations, procedures or treatments would have been recorded in either the out-patient or in-patient notes, as the same set of case-notes was used throughout the hospital. It is, however, possible that some consultations may not have been recorded. Information on sexual orientation and other risk factors for HIV infection relied on self-reporting and accurate recording in the case-notes. A discrepancy may have existed between stated sexual orientation and behaviour. However, a recent study performed at the Genitourinary clinic at St Mary's found a high degree of concordance between reported behaviour and stated sexual orientation in clinic attenders. 9 The study included only services obtained at St Mary's Hospital. Though primarily managed at St Mary's Hospital, patients may have received care from a variety of other sources. For instance, they could have had the terminal phase of their illness managed at home, or in a local hospital or hospice. Some of the routine drugs may also have been prescribed by general practitioners (GPs) during the patient's disease course, though many of the HIV-related drugs were likely to have been prescribed at St Mary's. Therefore, the patterns described are likely to be an underestimate of total treatment received and resources used. However, McCann's study on HIV-infected homosexual men in 1988-1989 -many of whom were part of our studydemonstrated that during the study period these patients used relatively few services outside the HIV clinic.
10 '" Of her sample of 263 HIV-infected men, only 126 (48 per cent) had a GP who knew their HIV status, and only 88 (34 per cent) had informed the doctor themselves." Furthermore, the work of the St Mary's Home Care Team was also included in the costing exercise for the study. The issue of multi-agency care provision can, however, only be reliably determined by following a group of patients prospectively. 12 Because of the complexity and multiplicity of possible diagnostic combinations which occur as a manifestation of symptomatic HIV disease, various combinations had to be aggregated into single diagnostic groups. Although service use and costs were analysed for particular outcomes, the absence of pathophysiological data on case-severity means that the analyses can only describe associations. Future work will aim to integrate service utilization, economic data and pathophysiological indices of case-severity, to assess particular outcomes.
Despite the limitations of our methods, the data collected were sufficiently robust to demonstrate a considerable range of service use and associated costs between diagnostic categories, with costs ranging from £8163 to £42124 per patient-year compared with an estimated cost of £17880 for the 'average' AIDS category. 2 For those categories where cost trends could be calculated, most were similar to those observed for service use and costs for the aggregated AIDS category.
2 ' 3 Costs per patient-year decreased over time owing to a shift from an in-patient-to an out-patient-based service.
An increase in out-patient costs per patient-year for the various combinations occurred in most diagnostic groups, with a reduction in in-patient expenditure for cases diagnosed since 1987. The notable exception to these trends was the PCP + OT category, in which there was an increase in in-patient expenditure and costs per patient-year were substantially greater than for the other PCP categories. A substantial variation in average costs of out-patient visits for different AIDS defining conditions was observed, ranging from £99 to £411 per visit.
No published UK studies have to date analysed use of services and associated costs in such detail as presented in this study. One recent study of another London HIV clinic observed a similar reduction in use of in-patient services for AIDS patients. 13 Similarly, more recent costing exercises, performed in Sheffield, 14 Newcastle 15 and London, 16 produced comparable costs for the treatment of AIDS patients to our original findings. 23 None of the UK studies published to date have produced data on costs for specific AIDS defining categories, which may be partly attributable to the smaller sample sizes of these studies. One US study 17 did report similar differences between patients who presented with PCP compared with those with KS. The former group used more hospital resources, leading to higher costs compared with the latter. Likewise, a recently published Dutch study described the complex relationship between casemix, use of services and associated costs. 18 Furthermore, none of the studies performed to date will have been able to assess the full economic ramifications of the introduction into routine clinical use of zalcitabine (ddQ and didanosine (ddl) since 1994, nor the introduction of combination anti-retroviral therapy. 19 " 21 The Importance of developing appropriate services for people with different manifestations of symptomatic HIV disease not only has clinical importance but also influences resource allocation for the provision of appropriate, effective and efficient services for people with HIV disease. The study highlights the effect of casemix on use and costs of services. Greater complexity of illness, consequent on increasing immunosuppression, was generally reflected in increased use of services and costs per patient-year. Although current resource allocation and purchasing is done using average costs per AIDS patient-year, for full implementation of the commissioning process local providers will need to be aware of the potential impact of casemix on the use and cost of service provision. Those units which treat more individuals with intractable opportunistic illnesses could incur greater costs for service provision, which could be in excess of the remuneration received if solely based on average costs per 'undifferentiated' AIDS patient-year. This is because costs for different AIDS defining conditions range widelyfrom £8163 to £42124 per patient-year -compared with an estimated average cost of £17 880 per 'undifferentiated' AIDS patient-year. Similarly, for extracontractual referrals, though the average costs of inpatient days only varied between £334 and £433 per inpatient day, greater variation was observed for average costs per out-patient visit for different AIDS defining conditions, ranging between £99 and £411 per visit. If the commissioning process is to be fully implemented, both purchasers and providers will need to take account of variations in casemix and associated costs when drawing up contracts or when cross-charging for inpatient or out-patient service provision for HIV infection in accordance with other medical conditions. 22
